default author photo

Alessandro Morabito

Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale

SCHOLARLY PAPERS

1

DOWNLOADS

82

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezolizumab in Patients with Previously Untreated PD-L1-High, Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study

Number of pages: 36 Posted: 19 Sep 2025
solange peters, Roy Herbst, Hidehito Horinouchi, Luis Paz Ares, Melissa Johnson, Benjamin J. Solomon, Mahmut Gumus, Mustafa Erman, Igor Bondarenko, Dong-Wan Kim, Enriqueta Felip, Alessandro Morabito, Maciej Bryl, Urbán László, Kaname Nosaki, Martin Reck, Raymond Meng, Chipman Stroud, Palak Kundu, Xiaohui Wen, Namrata S. Patil, Meilin Huang, Sarah Troutman, Christina Matheny and Byoung Chul Cho
Centre Hospitalier Universitaire Vaudois (CHUV), Yale University, National Cancer Center Hospital, University Hospital 12 de Octubre, Sarah Cannon Research Institute, Peter MacCallum Cancer Centre, Istanbul Medeniyet University, Hacettepe University, Dniprovsky State Medical University, Seoul National University - Department of Internal Medicine, Hospital Vall d’Hebron, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale, E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Matrahaza University, National Cancer Center Hospital East, German Centre for Lung Research - Lungen Clinic Grosshansdorf, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco, Genentech, Inc. - San Francisco and Yonsei University - Yonsei Cancer Center
Downloads 82 (790,029)

Abstract:

Loading...

Non-small cell lung cancer, NSCLC, immune checkpoint inhibitors, anti-TIGIT monoclonal antibody, PD-L1 inhibitor, atezolizumab, tiragolumab, cancer immunotherapy